Regorafenib combined with programmed cell death-1 inhibitor against refractory colorectal cancer and the platelet-to-lymphocyte ratio’s prediction on effectiveness

Table 3 Treatment-related adverse event

Adverse event	Number of patients (n = 30), n (%)
	Any grade	Grade 1-2	Grade 3
Any event	17 (56.7)	13 (43.3)	4 (13.3)
Hand-foot syndrome	10 (33.3)	8 (26.7)	2 (6.7)
Hypertension	7 (23.3)	7 (23.3)	0
Malaise	6 (20.0)	6 (20.0)	0
Gastrointestinal reaction	5 (16.7)	5 (16.7)	0
Transaminase elevation	4 (13.3)	3 (10.0)	1 (3.3)
Diarrhea	3 (10.0)	3 (10.0)	0
Abnormal capillary proliferation	2 (6.7)	1 (3.3)	1 (3.3)
Hypothyroidism	2 (6.7)	2 (6.7)	0
Proteinuria	2 (6.7)	2 (6.7)	0
Rash	2 (6.7)	2 (6.7)	0
Thrombocytopenia	2 (6.7)	2 (6.7)	0
Anemia	1 (3.3)	1 (3.3)	0
Myocardial enzyme elevation	1 (3.3)	1 (3.3)	0
Oral mucositis	1 (3.3)	1 (3.3)	0
Leukopenia/neutropenia	0	0	0